{
  "metadata": {
    "case_id": 4,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-28T03:46:18.927800",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/4_NCT03781726.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/4_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.78,
          0.19
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "label": "Treatment with glecaprevir/pibrentasvir Fixed Dose Combination",
            "type": "EXPERIMENTAL",
            "description": "8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir",
            "interventionNames": [
              "Drug: glecaprevir/pibrentasvir treatment"
            ]
          },
          "pred_item": {
            "label": "HCV D-RNA-positive/R-negative KT recipients",
            "type": "EXPERIMENTAL",
            "description": "Patients who underwent HCV D-RNA-positive/R-negative kidney transplantation (KT) and began 8 weeks of oral glecaprevir/pibrentasvir (G/P) between days 2 and 5 post-KT.",
            "interventionNames": [
              "Glecaprevir/pibrentasvir",
              "HCV-viremic Kidney Transplantation"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.18
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "glecaprevir/pibrentasvir treatment",
            "description": "combination treatment with glecaprevir and pibrentasvir fixed dose tablet.",
            "armGroupLabels": [
              "Treatment with glecaprevir/pibrentasvir Fixed Dose Combination"
            ],
            "otherNames": [
              "Mavyret treatment"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Glecaprevir/pibrentasvir",
            "description": "8 weeks of oral glecaprevir/pibrentasvir (G/P) initiated 2 to 5 days post-KT.",
            "armGroupLabels": [
              "HCV D-RNA-positive/R-negative KT recipients"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Undetectable HCV",
            "description": "HCV RNA \\< LLOQ 12 weeks after the last actual dose of G/P",
            "timeFrame": "12 weeks post treatment"
          },
          "pred_item": {
            "measure": "HCV cure (Sustained Virologic Response at 12 weeks)",
            "description": "Defined as undetectable plasma HCV RNA.",
            "timeFrame": "12 weeks after completion of glecaprevir/pibrentasvir (G/P)"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 9,
      "similarity_matrix": [
        [
          0.05,
          0.12,
          0.07,
          0.08,
          0.1,
          0.0,
          0.3,
          0.2,
          0.1
        ],
        [
          0.05,
          0.1,
          0.1,
          0.05,
          0.08,
          0.05,
          0.68,
          0.4,
          0.1
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 7,
          "score": 0.2,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Subjects With On-treatment Virologic Failure",
            "description": "HCV RNA \\> LLOQ during G/P treatment",
            "timeFrame": "During 8 week treatment course"
          },
          "pred_item": {
            "measure": "HCV antibody status",
            "description": "Assessment of the presence of HCV antibodies.",
            "timeFrame": "1 year post-transplant"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 6,
          "score": 0.68,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Subjects With Post-treatment Virologic Relapse",
            "description": "HCV RNA \\> LLOQ after completion of G/P treatment and prior HCV RNA \\< LLOQ while on treatment",
            "timeFrame": "During 12 week post treatment follow-up"
          },
          "pred_item": {
            "measure": "HCV RNA level",
            "description": "Measurement of Hepatitis C virus RNA levels.",
            "timeFrame": "24 weeks after G/P completion"
          }
        }
      ]
    }
  ]
}